Chimeric antigen receptors in cancer immuno-gene therapy: Current status and future directions

International Reviews of Immunology

Volumn 30, Issue 5-6, 2011, Pages 294-311

  Chicaybam, Leonardo ^a   Laino Sodré, Andressa ^a   Bonamino, Martin ^a  

^a Instituto Nacional de Cncer   (Brazil)

Author keywords

Cancer; Chimeric Antigen Receptors; Gene Therapy; Immunotherapy

Indexed keywords

ANGIOTENSIN III; CD19 ANTIBODY; CD20 ANTIBODY; CD28 ANTIGEN; CHIMERIC ANTIBODY; GLYCOPROTEIN GP 100; INTERLEUKIN 13; INTERLEUKIN 15; LYMPHOCYTE ANTIGEN RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN;

ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; COLON CARCINOMA; FOLLICULAR LYMPHOMA; GENE TARGETING; GENE THERAPY; GLIOBLASTOMA; IMMUNOGLOBULIN GENE; IN VIVO STUDY; KIDNEY CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUICIDE GENE; T LYMPHOCYTE; TUMOR CELL;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 80755130162     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2011.595855     Document Type: Article

References (98)

1. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233-5239.
2. Gross G, Gorochov G, Waks T, Eshhar Z. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc. 1989;21(1 Pt 1):127-130. (Pubitemid 19117939)
3. Eshhar Z,Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720-724. (Pubitemid 23028937)
4. Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia. 2007;21(9):1859-1874. (Pubitemid 47299958)
5. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol. 2004;172(1):104-113. (Pubitemid 38020461)
6. Giordano Attianese GM,Marin V, Hoyos V, et al. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood. 2011;117(18):4736-4745.
7. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24(13):e20-e22.
8. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112(6):2261-2271.
9. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumorspecific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264-1270.
10. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099-4102.
11. Brentjens R, Yeh R, Bernal Y, Riviere I, SadelainM. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.MolTher. 2010;18(4):666-668.
12. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.MolTher. 2010;18(4):843-851.
13. Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RL, Chames P. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther. 2001;8(21):1601-1608. (Pubitemid 33085581)
14. Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RL. T cell retargeting with MHC class Irestricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol. 2005;174(12):7853-7858. (Pubitemid 40806294)
15. Stewart-Jones G, Wadle A, Hombach A, et al. Rational development of high-affinity T-cell receptorlike antibodies. Proc Natl Acad Sci U S A. 2009;106(14):5784-5788.
16. Li Y, Depontieu FR, Sidney J et al. Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells. JMol Biol. 2010;399(4):596-603.
17. Petersen J,Wurzbacher SJ,WilliamsonNA, et al.Phosphorylated self-peptides alterhuman leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes. Proc Natl Acad Sci U S A. 2009;106(8):2776- 2781.
18. Depontieu FR, Qian J, Zarling AL, et al. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc Natl Acad Sci U S A. 2009;106(29):12073-12078.
19. Altenschmidt U, Kahl R, Moritz D, et al. Cytolysis of tumor cells expressing the Neu/erbB- 2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res. 1996;2(6):1001-1008. (Pubitemid 26198470)
20. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastomamultiformeby interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004;64(24):9160-9166. (Pubitemid 39665531)
21. Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE.The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol. 2010;184(12):6938-6949.
22. Bridgeman JS,Hawkins RE,Hombach AA, et al. Building better chimeric antigen receptors for adoptive T cell therapy. Curr GeneTher. 2010;10(2):77-90.
23. Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J ExpMed. 1995;181(5):1653-1659.
24. Brocker T.Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood. 2000;96(5):1999-2001. (Pubitemid 30661090)
25. Roberts MR, Cooke KS, Tran AC, et al. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains. J Immunol. 1998;161(1):375-384. (Pubitemid 28285545)
26. Haynes NM, Snook MB, Trapani JA, et al. Redirectingmouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RIgamma. J Immunol. 2001;166(1):182-187. (Pubitemid 32038431)
27. Heuser C, Hombach A, Losch C, Manista K, Abken H. T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells. GeneTher. 2003;10(17):1408-1419. (Pubitemid 36987134)
28. Zhao Y,Wang QJ, Yang S, et al. A herceptin-based chimeric antigen receptor withmodified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol. 2009;183(9):5563-5574.
29. Yun CO, Nolan KF, BeechamEJ, Reisfeld RA, Junghans RP. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia. 2000;2(5):449-459. (Pubitemid 32044791)
30. Stephan MT, Ponomarev V, Brentjens RJ, et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. NatMed. 2007;13(12):1440-1449. (Pubitemid 350224246)
31. Gade TP, Hassen W, Santos E, et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 2005;65(19):9080-9088. (Pubitemid 41377401)
32. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13(18 Pt 1):5426-5435. (Pubitemid 47510370)
33. Mueller DL.Mechanismsmaintaining peripheral tolerance. Nat Immunol. 2010;11(1):21-27.
34. Cooper LJ, Al-Kadhimi Z, Serrano LM, et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood. 2005;105(4):1622-1631. (Pubitemid 40223683)
35. SavoldoB,RooneyCM,Di StasiA, et al.EpsteinBarr virus specific cytotoxicTlymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110(7):2620-2630. (Pubitemid 47523186)
36. AcutoO,Michel F.CD28-mediated co-stimulation: a quantitative support for TCRsignalling.Nat Rev Immunol. 2003;3(12):939-951. (Pubitemid 37521536)
37. Croft M.The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9(4):271-285.
38. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9(3): 279-286. (Pubitemid 36362782)
39. Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006;66(22):10995-11004. (Pubitemid 44876999)
40. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009;106(9):3360-3365.
41. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.Mol Ther. 2009;17(8):1453-1464.
42. + T cell-mediated tumor eradication. Mol Ther. 2010;18(2):413-420.
43. Yvon E, Del Vecchio M, Savoldo B, et al. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009;15(18):5852-5860.
44. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121(5): 1822-1826.
45. Hoyos V, Savoldo B, Quintarelli C, et al. Engineering CD19-specific T lymphocytes with interleukin- 15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010;24(6):1160-1170.
46. Di Stasi A,De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113(25):6392-6402.
47. Craddock JA, Lu A, Bear A, et al. Enhanced tumor trafficking ofGD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010;33(8):780-788.
48. Moon EK, Carpenito C, Sun J, et al. Expression of a functional CCR2 receptor enhances tumor localization and eradication by human T cells expressing amesothelin-specific chimeric antibody receptor. Clin Cancer Res. Published onlineMay 24, 2011, doi: 10.1158/1078-0432.CCR-11-0351.
49. + T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118(1):294-305.
50. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005;102(27):9571-9576. (Pubitemid 40981722)
51. Singh H,Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008;68(8):2961-2971. (Pubitemid 351556297)
52. + T cells. J Clin Invest. 2005;115(6):1616-1626. (Pubitemid 40814670)
53. Yang S, Luca G, Liu F, et al. In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunol Immunother. 2011;60(5):739-749.
54. + T cells with effector and central memory-like phenotype. Gene Ther. 2010;17(9):1105-1116.
55. Popplewell L.Genetically engineered lymphocyte therapy after peripheral blood stem cell transplant in treating patients with high-risk, intermediate-grade, B-cell non-Hodgkin lymphoma. National Clinical Trials [Internet]. 2011 Mar 16; NCT01318317. Available from: linicaltrials.gov/ct2/ show/record/NCT01318317
56. + T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A. 2009;106(41):17469-17474.
57. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106(1):376-383. (Pubitemid 40967217)
58. Muller T, Uherek C,Maki G, et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother. 2008;57(3):411-423. (Pubitemid 350295385)
59. Marin V, Dander E, Biagi E, et al. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol. 2006;34(9):1219-1229.
60. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174(2):817-826. (Pubitemid 40094277)
61. Chan CH, Stanners CP. Novel mousemodel for carcinoembryonic antigen-based therapy.Mol Ther. 2004;9(6):775-785. (Pubitemid 38878124)
62. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizesmurine CD19 can eradicate lymphoma and normal B cells. Blood. 2010;116(19):3875-3886.
63. Cheadle EJ,Hawkins RE, Batha H, O'Neill AL, Dovedi SJ, GilhamDE. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol. 2010;184(4):1885-1896.
64. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007;7(2):118-130. (Pubitemid 46174859)
65. Lee JC, Hayman E, Pegram HJ, et al. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 2011;71(8):2871-2881.
66. Pike-Overzet K, van der Burg M, Wagemaker G, van Dongen JJ, Staal FJ. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol Ther. 2007;15(11):1910-1916. (Pubitemid 350011729)
67. + lymphoidmalignancies.Mol Ther. 2008;16(3):580-589. (Pubitemid 351314999)
68. Manuri PV,WilsonMH,Maiti SN, et al. piggyBac transposon/transposase system to generate CD19- specific T cells for the treatment of B-lineagemalignancies. Hum Gene Ther. 2010;21(4):427-437.
69. Jin Z,Maiti S,Huls H, et al.The hyperactive SleepingBeauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther. 2011.
70. Bonini C, Grez M, Traversari C, et al. Safety of retroviral genemarkingwith a truncatedNGF receptor. NatMed. 2003;9(4):367-369. (Pubitemid 36460048)
71. Newrzela S, Cornils K, Li Z, et al. Resistance of mature T cells to oncogene transformation. Blood. 2008;112(6):2278-2286.
72. DeKelver RC, Choi VM, Moehle EA, et al. Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res. 2010;20(8):1133-1142.
73. Zou J, Sweeney CL, Chou BK, et al. Oxidase deficient neutrophils fromX-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease mediated safe harbor targeting. Blood. 2011.
74. Zhao Y, Moon E, Carpenito C, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010;70(22):9053-9061.
75. Mitsuyasu RT, Anton PA,Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood. 2000;96(3):785-793. (Pubitemid 30616838)
76. + cytotoxic T lymphocytes.MolTher. 2004;9(4):577-586. (Pubitemid 38578808)
77. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.MolTher. 2007;15(4):825-833. (Pubitemid 46432004)
78. KershawMH,Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using genemodified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106-6115. (Pubitemid 44703776)
79. Brentjens R, Riviere I. Laboratory-treated T cells with or without cyclophosphamide in treating patients with refractory chronic lymphocytic leukemia. National Clinical Trials [Internet]. 2007 Apr 25; NCT00466531. Available from: clinicaltrials.gov/ct2/show/NCT00466531
80. Brentjens R. Precursor B cell acute lymphoblastic leukemia (B-ALL) treated with autologous T cells genetically targeted to the B cell specific antigen CD19. National Clinical Trials [Internet]. 2010 Jan 6; NCT01044069. Available from: clinicaltrials.gov/ct2/show/NCT01044069
81. Ertl HC, Zaia J, Rosenberg SA, et al. Considerations for the clinical application of chimeric antigen receptor T cells: observations froma Recombinant DNA Advisory Committee symposium held June 15, 2010. Cancer Res. 2011;71(9):3175-3181.
82. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276(5319):1719-1724. (Pubitemid 27421983)
83. Di Stasi A, Tey SK, Fujita Y, et al. CASPALLO: Phase I clinical trial of allodepleted T cells transduced with inducible caspase 9 suicide gene after haploidentical stem cell transplantation. ASH Annual Meeting Abstracts 2010;116(21):559-.
84. SerafiniM, BonaminoM, Golay J, IntronaM. Elongation factor 1 (EF1alpha) promoter in a lentiviral backbone improves expression of the CD20 suicide gene in primary T lymphocytes allowing efficient rituximab-mediated lysis. Haematologica. 2004;89(1):86-95. (Pubitemid 38165859)
85. SerafiniM,Manganini M, Borleri G, et al. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. HumGene Ther. 2004;15(1):63-76. (Pubitemid 38147189)
86. Vogler I, Newrzela S, Hartmann S, et al. An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol Ther. 2010;18(7):1330- 1338.
87. Kershaw MH, Teng MW, Smyth MJ, Darcy PK. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol. 2005;5(12):928-940. (Pubitemid 41746762)
88. Varela-Rohena A, Carpenito C, Perez EE, et al. Genetic engineering of T cells for adoptive immunotherapy. Immunol Res. 2008;42(1-3):166-181.
89. Duong CP, Westwood JA, Berry LJ, Darcy PK, Kershaw MH. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy. 2011;3(1):33-48.
90. . ESGCT Poster presentations. XVIII Annual Congress of the European Society ofGene and Cell Therapy. HumGeneTher. 2010; 21:1397-1488.
91. Turatti F, Figini M, Balladore E, et al. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother. 2007;30(7):684-693. (Pubitemid 47480752)
92. Chmielewski M, Hombach A, Heuser C, et al. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004;173(12):7647-7653. (Pubitemid 39628207)
93. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-129. (Pubitemid 44547756)
94. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535-546.
95. Bendle GM, Linnemann C, Hooijkaas AI, et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. NatMed. 2010;16(5):565-570, 1p following 70.
96. Rosenberg SA. Of mice, not men: no evidence for graft-versus-host disease in humans receiving Tcell receptor-transduced autologous T cells.Mol Ther. 2010;18(10):1744-1745.
97. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917-924..
98. Guest RD, Hawkins RE, Kirillova N, et al.The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother. 2005;28(3):203-211. (Pubitemid 40593985)